Home › Calculator › ENSC Dividend Calculator 2026
ENSC Dividend DRIP Calculator 2026
704.23% YieldHealthcareEnsysce Biosciences, Inc. · NASDAQ
Price: $0.28 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When ENSC pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your ENSC snowball 📈
$10,000 in ENSC → $518.62M in 10 years · $295,190.49/month
About Ensysce Biosciences, Inc. (ENSC) — Dividend Analysis 2026
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
Compare ENSC with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full ENSC DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open ENSC position with:
🌍 ENSC Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold ENSC.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 704.23% | 701.43% | $70,423 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 598.60% | 595.80% | $59,860 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 563.38% | 560.58% | $56,338 / yr |
| 🇬🇧 UK ISA | 0% | 704.23% | 701.43% | $70,423 / yr |
| 🇬🇧 UK Taxable | 8.75% | 642.61% | 639.81% | $64,261 / yr |
| 🇨🇦 TFSA | 0% | 704.23% | 701.43% | $70,423 / yr |
| 🇨🇦 CA Taxable | 25% | 528.17% | 525.37% | $52,817 / yr |
| 🇦🇺 Super (pension) | 15% | 598.60% | 595.80% | $59,860 / yr |
| 🇦🇺 AU Taxable | 30% | 492.96% | 490.16% | $49,296 / yr |
| 🇩🇪 DE Taxable | 26.375% | 518.49% | 515.69% | $51,849 / yr |
| 🇫🇷 FR Taxable | 30% | 492.96% | 490.16% | $49,296 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 ENSC Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 ENSC Dividend Payment Schedule
ENSC pays quarterly — 4 times per year. Next ex-div: TBD.
📊 ENSC vs Healthcare Benchmarks
How ENSC compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ENSC sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ ENSC Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Buy | 2023-03-02 | 90,287 | $0.49 | $44.1K | ||
| Buy | 2023-03-01 | 270,000 | $0.48 | $129.0K | ||
| Buy | 2023-02-28 | 109,300 | $0.49 | $53.4K | ||
| Buy | 2022-12-09 | 357,143 | $1.40 | $500.0K | ||
| A-Award | 2022-12-09 | 714,286 | $1.40 | $1.00M | ||
| A-Award | 2022-06-23 | 15,000 | — | — | ||
| A-Award | 2022-06-23 | 15,000 | — | — | ||
| A-Award | 2022-06-23 | 15,000 | — | — | ||
| A-Award | 2022-06-23 | 15,000 | $0.42 | $6.4K | ||
| A-Award | 2022-06-23 | 15,000 | — | — |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ENSC dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Ensysce Biosciences, Inc. (ENSC) is currently trading at $0.28, trading near its 52-week low. The current dividend yield is 704.23% based on an annual payout of $2.00 per share.
ENSC (Ensysce Biosciences, Inc.) — 704.23% Dividend Yield Analysis
Ensysce Biosciences, Inc. (ENSC) is a healthcare stock currently trading at $0.28 with a dividend yield of 704.23%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (704.23%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.